137 related articles for article (PubMed ID: 25016818)
1. [Therapeutic monoclonal antibodies for hematological diseases].
Harada T; Abe M
Nihon Rinsho; 2014 Jun; 72(6):1143-8. PubMed ID: 25016818
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors.
Charmsaz S; Scott AM; Boyd AW
Exp Hematol; 2017 Oct; 54():31-39. PubMed ID: 28751189
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE
Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221
[TBL] [Abstract][Full Text] [Related]
4. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies.
Christiaansen JE; Sears DW
Cancer Res; 1984 Sep; 44(9):3712-8. PubMed ID: 6744288
[TBL] [Abstract][Full Text] [Related]
5. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
[TBL] [Abstract][Full Text] [Related]
6. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
Overdijk MB; Verploegen S; van den Brakel JH; Lammerts van Bueren JJ; Vink T; van de Winkel JG; Parren PW; Bleeker WK
J Immunol; 2011 Sep; 187(6):3383-90. PubMed ID: 21832160
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antitumor effects of BCG and monoclonal antibodies capable of inducing antibody-dependent cell-mediated cytotoxicity.
Komuta K; Kawase I; Ogura T; Masuno T; Yokota S; Hosoe S; Ikeda T; Shirasaka T; Kishimoto S
Jpn J Cancer Res; 1987 Feb; 78(2):185-92. PubMed ID: 3104261
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
10. Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies.
Capietto AH; Keirallah S; Gross E; Dauguet N; Laprévotte E; Jean C; Gertner-Dardenne J; Bezombes C; Quillet-Mary A; Poupot M; Ysebaert L; Laurent G; Fournié JJ
Curr Drug Targets; 2010 Jul; 11(7):790-800. PubMed ID: 20370648
[TBL] [Abstract][Full Text] [Related]
11. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
12. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.
Iannello A; Ahmad A
Cancer Metastasis Rev; 2005 Dec; 24(4):487-99. PubMed ID: 16408158
[TBL] [Abstract][Full Text] [Related]
13. The next generation of antibody-drug conjugates comes of age.
Beck A; Haeuw JF; Wurch T; Goetsch L; Bailly C; Corvaïa N
Discov Med; 2010 Oct; 10(53):329-39. PubMed ID: 21034674
[TBL] [Abstract][Full Text] [Related]
14. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic monoclonal antibodies in hemato-oncology].
Gennigens C; Collignon J; Jerusalem G; Rorive A; Sautois B
Rev Med Liege; 2009; 64(5-6):264-7. PubMed ID: 19642456
[TBL] [Abstract][Full Text] [Related]
16. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies as therapeutics in human malignancies.
Pandey M; Mahadevan D
Future Oncol; 2014 Mar; 10(4):609-36. PubMed ID: 24754592
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.
van de Donk NW; Kamps S; Mutis T; Lokhorst HM
Leukemia; 2012 Feb; 26(2):199-213. PubMed ID: 21852787
[TBL] [Abstract][Full Text] [Related]
19. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies in hematological malignancies: past, present and future.
Tazi I; Nafil H; Mahmal L
J Cancer Res Ther; 2011; 7(4):399-407. PubMed ID: 22269399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
